Health Care [ 4/12 ] | Pharmaceuticals [ 9/75 ]
NASDAQ | Common Stock
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma.
It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F.
Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA.
The company was incorporated in 1990 and is headquartered in San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 13, 26 | -1.29 Decreased by -759.87% | -3.50 Increased by +63.10% |
| Nov 6, 25 | -1.87 Decreased by -938.89% | -0.19 Decreased by -869.92% |
| Aug 8, 25 | -2.95 Decreased by -1.08 K% | -0.20 Decreased by -1.38 K% |
| May 7, 25 | -0.24 Decreased by -26.53% | -0.19 Decreased by -26.53% |
| Mar 3, 25 | -0.15 Increased by +31.82% | -0.20 Increased by +23.08% |
| Nov 7, 24 | -0.18 Increased by +25.00% | -0.21 Increased by +14.29% |
| Aug 8, 24 | -0.25 Increased by +7.41% | -0.20 Decreased by -25.00% |
| May 9, 24 | -0.19 Increased by +40.63% | -0.19 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 21.81 M Decreased by -25.25% | -36.08 M Decreased by -596.89% | Decreased by -165.45% Decreased by -764.77% |
| Sep 30, 25 | 11.79 M Decreased by -51.13% | -35.52 M Increased by +4.14% | Decreased by -301.29% Decreased by -96.14% |
| Jun 30, 25 | 11.18 M Decreased by -52.42% | -41.59 M Increased by +20.57% | Decreased by -372.20% Decreased by -66.96% |
| Mar 31, 25 | 10.46 M Decreased by -51.66% | -50.88 M Decreased by -38.26% | Decreased by -486.44% Decreased by -186.02% |
| Dec 31, 24 | 29.18 M Increased by +22.15% | 7.26 M Increased by +117.26% | Increased by +24.89% Increased by +114.13% |
| Sep 30, 24 | 24.12 M Decreased by -0.08% | -37.06 M Increased by +19.15% | Decreased by -153.61% Increased by +19.09% |
| Jun 30, 24 | 23.49 M Increased by +14.59% | -52.36 M Decreased by -2.43% | Decreased by -222.93% Increased by +10.61% |
| Mar 31, 24 | 21.64 M Increased by +0.21% | -36.80 M Increased by +73.14% | Decreased by -170.07% Increased by +73.20% |